RESEARCH PEPTIDE FUNDAMENTALS / MATRIX
Four Peptides, Four Different Evidence Ladders
How ipamorelin, PT-141, semaglutide, and tirzepatide differ not just in mechanism, but in how much of what is claimed about them has actually been tested in humans.
The short version
This page lines up ipamorelin, PT-141, semaglutide, and tirzepatide on the dimensions that matter most to a skeptical reader: what receptor each one acts on, what has actually been tested in humans, how strong that testing was, and what remains unresolved. The headline finding is not subtle. These four compounds occupy wildly different points on an evidence ladder. Two are backed by large, multi-thousand-person randomized trials and current FDA approval for broad use. One is FDA-approved, but for a single narrow indication far smaller than its research-community reputation. One has a single human trial to its name, and that trial did not succeed. None of this is medical advice, and no dose is recommended anywhere on this page.
The comparison matrix
| Dimension | Ipamorelin | PT-141 (bremelanotide) | Semaglutide | Tirzepatide |
|---|---|---|---|---|
| Peptide class | Selective GH secretagogue (GHS-R1a agonist, pentapeptide) | Melanocortin (MC4R/MC3R) agonist, cyclic heptapeptide | GLP-1 receptor agonist, 31-aa peptide | Dual GIP/GLP-1 receptor agonist, 39-aa peptide |
| Human trial record | One placebo-controlled RCT (n=114) — missed its primary endpoint [3] | Two Phase 3 RCTs (n=1,267) plus a 52-week extension — met endpoints [10][11] | Multiple large Phase 3 trials across four indications, tens of thousands of participants [14][15][16] | Multiple large Phase 3 trials, including a positive head-to-head win over semaglutide [13][20][21] |
| Regulatory status | Not approved for any indication | FDA-approved, HSDD in premenopausal women only | FDA-approved (diabetes, weight, cardiovascular risk, MASH) | FDA-approved (diabetes, weight, sleep apnea) |
| Strongest single data point | Founding mechanistic characterization in animals and cells [6] | RECONNECT Phase 3 program [10] | SELECT cardiovascular-outcomes trial, 20% relative risk reduction [15] | Head-to-head superiority over semaglutide, -20.2% vs -13.7% [13] |
| Where the evidence is weakest | Everything beyond the failed perioperative trial: sleep, recovery, and fat-loss claims rest on anecdote or animal data alone | Every use outside premenopausal HSDD: male use, general performance enhancement | Long-term cancer-signal questions a dedicated review still calls unresolved [17] | The specific mechanistic contribution of the GIP receptor arm |
Peptide class and mechanism
All four compounds are peptides engineered to survive longer in the body than their natural or unmodified counterparts would. Ipamorelin uses an artificial amino acid (Aib) and D-amino acid substitutions to block enzymatic breakdown of a five-residue chain [6]. PT-141 closes its structure into a stabilized ring with a lactam bridge. Semaglutide and tirzepatide both attach a fatty-acid arm to a lysine side chain, letting each peptide bind blood albumin and resist kidney clearance for roughly a week, though tirzepatide's arm is heavier and its receptor engagement more asymmetric, favoring GIP over GLP-1. None of these four act through a single, simple lock-and-key binding the way a small molecule typically does; each is a case study in engineering a fragile natural structure into something that survives long enough to be dosed weekly.
Human trial maturity
This is where the four genuinely separate. Ipamorelin's entire controlled human record is one perioperative trial that missed its primary endpoint [3] and one small pharmacokinetic study [4] — a thin foundation for the range of claims made about it in research-use communities. PT-141 has a real, positive Phase 3 program (1,267 participants across two trials, plus a 684-person extension) [10][11], but that program tested one specific population and one specific outcome, not the broader uses now built on top of it. Semaglutide has the deepest bench: multiple large outcome trials spanning diabetes, weight, cardiovascular, and kidney endpoints, several exceeding ten thousand participants [14][15][16]. Tirzepatide's program is comparably large [20][21] and includes something none of the other three has: a positive, prespecified head-to-head trial against an approved rival [13]. Read in order, the four compounds trace an almost complete spectrum from "one failed trial" to "one trial that beat the previous standard."
Regulatory status
Ipamorelin has never been approved by any regulator for any indication; its 2024 removal from the interim compounding-substances list was a tightening, not a loosening, of its regulatory standing. PT-141 (bremelanotide) is genuinely FDA-approved, but the approval covers exactly one population and one outcome: hypoactive sexual desire disorder in premenopausal women [10][12]. Semaglutide and tirzepatide are both broadly approved prescription medicines, each covering multiple indications, though semaglutide's approved footprint (diabetes, weight, cardiovascular risk, and MASH) is currently the wider of the two [14][15][16][18]. A reader trying to gauge how seriously to weigh a claim about any of these four compounds could do worse than starting with this one dimension alone.
Where each compound's uncertainty actually lives
For ipamorelin, the uncertainty is almost total: whether it does anything measurable in ongoing human use beyond a single trial that did not succeed [3]. For PT-141, the uncertainty is about generalization: the trials are solid, but they say nothing directly about the off-label populations that make up most of its research-community use [10][12]. For semaglutide, the uncertainty sits at the edges of an otherwise strong record: rare-event cancer signals a dedicated safety review says cannot yet be confirmed or ruled out [17]. For tirzepatide, the uncertainty is mechanistic and temporal: how much of its edge comes specifically from the GIP receptor rather than other factors [18], and what its safety profile looks like beyond the several years of data collected so far. Naming where the uncertainty lives, compound by compound, is the point of this whole comparison.